152 related articles for article (PubMed ID: 33040324)
1. Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.
Serra-García L; Bosch-Amate X; Alamon-Reig F; Giavedoni P; Fuertes I; Morgado-Carrasco D; Iglesias P; Puig S; Mascaró JM
Int J Dermatol; 2021 Jan; 60(1):e30-e32. PubMed ID: 33040324
[No Abstract] [Full Text] [Related]
2. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
Russo I; Filoni A; Alaibac M
Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
[No Abstract] [Full Text] [Related]
3. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
4. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
Chang ALS; Tran DC; Cannon JGD; Li S; Jeng M; Patel R; Van der Bokke L; Pague A; Brotherton R; Rieger KE; Satpathy AT; Yost KE; Reddy S; Sarin K; Colevas AD
J Am Acad Dermatol; 2019 Feb; 80(2):564-566. PubMed ID: 30145186
[No Abstract] [Full Text] [Related]
6. Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.
De Giorgi V; Trane L; Savarese I; Silvestri F; Venturi F; Zuccaro B; Scarfì F
Clin Exp Dermatol; 2021 Dec; 46(8):1612-1614. PubMed ID: 34157152
[No Abstract] [Full Text] [Related]
7. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP
Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047
[No Abstract] [Full Text] [Related]
8. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.
Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C
Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136
[No Abstract] [Full Text] [Related]
9. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
10. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
11. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
12. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
13. Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years.
Dumann K; Artz N; Ziemer M
JAMA Dermatol; 2021 Aug; 157(8):1004-1006. PubMed ID: 34232273
[No Abstract] [Full Text] [Related]
14. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?
Ravulapati S; Leung C; Poddar N; Tu Y
Am J Med; 2017 May; 130(5):e207-e208. PubMed ID: 28249663
[No Abstract] [Full Text] [Related]
15. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
[TBL] [Abstract][Full Text] [Related]
16. Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda).
Conger JR; Grob SR; Tao J
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e127. PubMed ID: 30925541
[No Abstract] [Full Text] [Related]
17. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
[No Abstract] [Full Text] [Related]
19. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.
Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N
Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728
[No Abstract] [Full Text] [Related]
20. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
[Next] [New Search]